首页> 外文期刊>Archives of medical research >Clinical, Histological and Molecular Characteristics of Mexican Patients with Fabry Disease and Significant Renal Involvement
【24h】

Clinical, Histological and Molecular Characteristics of Mexican Patients with Fabry Disease and Significant Renal Involvement

机译:墨西哥法布里病和严重肾脏受累患者的临床,组织学和分子特征

获取原文
获取原文并翻译 | 示例
           

摘要

Background and Aims: Fabry's disease (FD) is an X-linked lysosomal disorder caused by a deficiency of the enzyme α-galactosidase A that produces accumulation of glycosphingolipids with clinical abnormalities of skin, eye, kidney, heart, brain, and peripheral nervous system. We undertook this study to describe the molecular characteristics of the first four Mexican patients with diagnosis of FD with significant renal involvement, correlating these molecular characteristics with clinical, pathological and biochemical findings. Methods: Genomic DNA from Mexican nonrelated patients with presumptive diagnosis of FD was sequenced by polymerase chain reaction (PCR). DNA sequences were compared against sequences in world data bank gene for alpha-galactosidase A (α-GLA, ENSG00000102393) using the BLAST database. Results: Three patients were confirmed as having FD by displaying mutations in the α-GLA gene. The mutations found are a substitution (p.L243F) in patient 1, and a substitution (p.A156V) in patient 3. These two mutations had been previously reported. The new mutation was in patient 2 who displayed a deletion (c.260delA) changing the open reading frame from codon 86 and a stop codon at the 105th residue of the protein, (instead of 429 AA). The fourth patient had lack of mutations in any of the seven exons of α-GLA or 25 base-pair flanking regions; had mild manifestations with kidney histopathological diagnosis of FD that gave us a final diagnosis of atypical phenotype of FD. Conclusions: Although the sample is small, it gives a first idea of the molecular and clinical heterogeneity of FD in a Mexican population.
机译:背景与目的:法布里氏病(FD)是一种X连锁溶酶体疾病,由α-半乳糖苷酶A缺乏症引起,该酶产生糖鞘脂积聚,皮肤,眼睛,肾脏,心脏,大脑和外周神经系统出现临床异常。我们进行了这项研究,以描述前四名诊断为FD且患有严重肾脏病变的墨西哥患者的分子特征,并将这些分子特征与临床,病理和生化结果相关联。方法:采用聚合酶链反应(PCR)对墨西哥非相关性FD患者的基因组DNA进行测序。使用BLAST数据库,将DNA序列与世界数据库基因中的α-半乳糖苷酶A(α-GLA,ENSG00000102393)序列进行比较。结果:三名患者通过显示α-GLA基因突变被确认患有FD。发现的突变是患者1中的替代(p.L243F)和患者3中的替代(p.A156V)。这两个突变先前已有报道。新的突变发生在患者2中,该患者表现出一个缺失(c.260delA),改变了开放阅读框的86号密码子,并在该蛋白质的第105位残基处终止了密码子(而不是429 AA)。第四例患者在α-GLA的七个外显子或25个碱基对侧翼区域中的任何一个都没有突变。在FD的肾脏组织病理学诊断中具有轻度表现,这使我们对FD的非典型表型有了最终诊断。结论:尽管样本很小,但它为墨西哥人群中FD的分子和临床异质性提供了第一个思路。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号